Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 1.75 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-04-15
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-12-31 was 0.00 shares.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-09-30 was 0.00 shares.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-06-30 was 0.00 shares.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-03-31 was 33.00M shares.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2025 was 1.75M shares, a 94.70% decline from fiscal 2024.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 33.00M shares, a 22.78% decline from fiscal 2023.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 42.74M shares, a 293.34% increase from fiscal 2022.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 10.87M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.75M shares 10-K · filed 2026-04-15 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | 0.00 shares derived: sum of 2 quarters · filed 2026-04-15 | 0.00 shares derived: sum of 3 quarters · filed 2026-04-15 | 33.00M shares 10-K · filed 2026-04-15 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-17 | 33.00M shares 10-Q · filed 2025-11-17 | 33.00M shares derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 33.00M shares 10-Q · filed 2025-08-13 | 33.00M shares derived: sum of 3 quarters · filed 2025-08-13 | 33.00M shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 33.00M shares 10-Q · filed 2025-05-15 | 33.00M shares derived: sum of 2 quarters · filed 2025-05-15 | 33.00M shares derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | 0.00 shares derived: sum of 2 quarters · filed 2025-04-15 | 42.74M shares 10-K · filed 2025-04-15 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | 42.74M shares 10-Q · filed 2024-11-19 | ||
| 2023-06-30 | 42.74M shares 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | 1.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-12 | 1.25M shares derived: sum of 2 quarters · filed 2024-04-12 | 5.10M shares derived: sum of 3 quarters · filed 2024-04-12 | 10.87M shares 10-K · filed 2024-04-12 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 3.85M shares derived: sum of 2 quarters · filed 2023-11-14 | 9.62M shares 10-Q · filed 2023-11-14 | |
| 2022-06-30 | 3.85M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | 9.62M shares 10-Q · filed 2023-08-18 | ||
| 2022-03-31 | 5.77M shares 10-Q · filed 2023-05-22 | |||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | 0.00 shares derived: sum of 2 quarters · filed 2022-04-15 | 0.00 shares derived: sum of 3 quarters · filed 2022-04-15 | 18.03M shares 10-K · filed 2022-04-15 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-16 | 18.03M shares 10-Q · filed 2020-11-16 | 18.03M shares derived: sum of 4 quarters · filed 2021-04-15 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | 18.03M shares 10-Q · filed 2020-08-14 | 18.03M shares derived: sum of 3 quarters · filed 2021-04-15 | 20.73M shares derived: sum of 4 quarters · filed 2021-04-15 |
| 2020-03-31 | 18.03M shares 10-Q · filed 2020-06-29 | 18.03M shares derived: sum of 2 quarters · filed 2021-04-15 | 20.73M shares derived: sum of 3 quarters · filed 2021-04-15 | |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-15 | 2.70M shares derived: sum of 2 quarters · filed 2021-04-15 | 4.87M shares 10-K · filed 2021-04-15 | |
| 2019-09-30 | 2.70M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-19 | 4.87M shares 10-Q · filed 2019-11-19 | ||
| 2019-06-30 | 2.16M shares 10-Q · filed 2019-08-19 | |||
| 2018-12-31 | 1.61M shares 10-K · filed 2020-05-14 |